FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162295328> ?p ?o ?g. }

• W2162295328 endingPage "3335" @default.
• W2162295328 startingPage "3327" @default.
• W2162295328 abstract "Abstract Recombinant human erythropoietin (rHuEPO) stimulates erythropoietic bone marrow cells and increases erythrocyte production. This prospective study was designed to evaluate the effects of rHuEPO on regeneration of erythropoiesis after allogeneic or autologous bone marrow transplantation (BMT). Seventeen centers participated in this randomized, double-blind, placebo-controlled multicenter trial. The randomization was performed centrally for each center and stratified according to allogeneic or autologous BMT and major ABO-blood group incompatibility. One hundred and six patients received rHuEPO after allogeneic BMT and 109 patients received placebo. After autologous BMT, 57 patients were treated with rHuEPO and 57 with placebo. Patients received either 150 IU/kg/day C127 mouse-cell-derived rHuEPO or placebo as continuous intravenous infusion. Therapy started after bone marrow infusion and lasted until independence from erythrocyte transfusions for 7 consecutive days with stable hemoglobin levels > or = 9 g/100 mL or until day 41. After allogeneic BMT, the reticulocyte counts were significantly higher with rHuEPO from day 21 to day 42 after BMT. The median time (95% confidence intervals) to erythrocyte transfusion independence was 19 days (range, 16.3 to 21.6) with rHuEPO and 27 days (range, 22.3 to > 42) with placebo (P < .003). The mean (+/- SD) numbers of erythrocyte transfusions until day 20 after BMT were 6.6 +/- 4.8 with rHuEPO and 6.0 +/- 3.8 with placebo. However, from day 21 to day 41, the rHuEPO-treated patients received 1.4 +/- 2.5 (median, 0) transfusions and the control group received 2.7 +/- 4.0 (median, 2) transfusions (P = .004). In the follow-up period from day 42 up to day 100, 2.4 +/- 5.6 transfusions were required with rHuEPO and 4.5 +/- 9.6 were required with placebo (P = .075). A multivariate analysis (ANOVA) showed that acute graft-versus-host disease (GVHD), major ABO-blood group incompatibility, age greater than 35 years, and hemorrhage significantly increased the number of transfusions. However, after day 20, rHuEPO significantly reduced the number of erythrocyte transfusions in these patient groups, as well as reducing incompatibility in the major ABO-blood group. For the whole study period, rHuEPO reduced the transfusion requirements in GVHD III and IV from 18.4 +/- 8.6 to 8.5 +/- 6.8 U (P = .05). After autologous BMT, there was no difference in the time to independence from erythrocyte transfusions and in the regeneration of reticulocytes. Marrow purging strongly increased the requirement for transfusions as well as the time to transfusion independence." @default.
• W2162295328 created "2016-06-24" @default.
• W2162295328 creator A5001564808 @default.
• W2162295328 creator A5009095647 @default.
• W2162295328 creator A5017846397 @default.
• W2162295328 creator A5037473051 @default.
• W2162295328 creator A5049269263 @default.
• W2162295328 creator A5051760596 @default.
• W2162295328 creator A5059745295 @default.
• W2162295328 creator A5060864300 @default.
• W2162295328 creator A5068168305 @default.
• W2162295328 creator A5069015223 @default.
• W2162295328 date "1994-11-15" @default.
• W2162295328 modified "2023-10-02" @default.
• W2162295328 title "A controlled trial of recombinant human erythropoietin after bone marrow transplantation" @default.
• W2162295328 cites W103650626 @default.
• W2162295328 cites W127506052 @default.
• W2162295328 cites W136430207 @default.
• W2162295328 cites W145118746 @default.
• W2162295328 cites W1493658257 @default.
• W2162295328 cites W1501784999 @default.
• W2162295328 cites W1544569979 @default.
• W2162295328 cites W1554216517 @default.
• W2162295328 cites W1575336769 @default.
• W2162295328 cites W1592476307 @default.
• W2162295328 cites W1822925937 @default.
• W2162295328 cites W1902451473 @default.
• W2162295328 cites W1938538533 @default.
• W2162295328 cites W1969878310 @default.
• W2162295328 cites W1979300931 @default.
• W2162295328 cites W1996729197 @default.
• W2162295328 cites W2004723396 @default.
• W2162295328 cites W2005287301 @default.
• W2162295328 cites W2012327732 @default.
• W2162295328 cites W2017357770 @default.
• W2162295328 cites W2026083876 @default.
• W2162295328 cites W2026452824 @default.
• W2162295328 cites W2026594967 @default.
• W2162295328 cites W2047158162 @default.
• W2162295328 cites W2049186520 @default.
• W2162295328 cites W2050985097 @default.
• W2162295328 cites W2072606606 @default.
• W2162295328 cites W2076387115 @default.
• W2162295328 cites W2090361799 @default.
• W2162295328 cites W2105251987 @default.
• W2162295328 cites W2110612111 @default.
• W2162295328 cites W2119465215 @default.
• W2162295328 cites W2138293573 @default.
• W2162295328 cites W2245097108 @default.
• W2162295328 cites W2247195428 @default.
• W2162295328 cites W2274447942 @default.
• W2162295328 cites W2315613377 @default.
• W2162295328 cites W2320661627 @default.
• W2162295328 cites W2329804409 @default.
• W2162295328 cites W2331565502 @default.
• W2162295328 cites W233692421 @default.
• W2162295328 cites W2340124568 @default.
• W2162295328 cites W2407818103 @default.
• W2162295328 cites W2410079803 @default.
• W2162295328 cites W2411870978 @default.
• W2162295328 cites W2414989492 @default.
• W2162295328 cites W2415322150 @default.
• W2162295328 cites W2417737654 @default.
• W2162295328 cites W2418254983 @default.
• W2162295328 cites W2421254392 @default.
• W2162295328 cites W2433000321 @default.
• W2162295328 cites W2462099897 @default.
• W2162295328 cites W270802172 @default.
• W2162295328 cites W2796700885 @default.
• W2162295328 cites W2992851677 @default.
• W2162295328 cites W3025393355 @default.
• W2162295328 cites W85537202 @default.
• W2162295328 cites W2995133996 @default.
• W2162295328 doi "https://doi.org/10.1182/blood.v84.10.3327.3327" @default.
• W2162295328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7949088" @default.
• W2162295328 hasPublicationYear "1994" @default.
• W2162295328 type Work @default.
• W2162295328 sameAs 2162295328 @default.
• W2162295328 citedByCount "76" @default.
• W2162295328 countsByYear W21622953282012 @default.
• W2162295328 countsByYear W21622953282013 @default.
• W2162295328 countsByYear W21622953282014 @default.
• W2162295328 countsByYear W21622953282016 @default.
• W2162295328 countsByYear W21622953282017 @default.
• W2162295328 countsByYear W21622953282019 @default.
• W2162295328 crossrefType "journal-article" @default.
• W2162295328 hasAuthorship W2162295328A5001564808 @default.
• W2162295328 hasAuthorship W2162295328A5009095647 @default.
• W2162295328 hasAuthorship W2162295328A5017846397 @default.
• W2162295328 hasAuthorship W2162295328A5037473051 @default.
• W2162295328 hasAuthorship W2162295328A5049269263 @default.
• W2162295328 hasAuthorship W2162295328A5051760596 @default.
• W2162295328 hasAuthorship W2162295328A5059745295 @default.
• W2162295328 hasAuthorship W2162295328A5060864300 @default.
• W2162295328 hasAuthorship W2162295328A5068168305 @default.
• W2162295328 hasAuthorship W2162295328A5069015223 @default.
• W2162295328 hasBestOaLocation W21622953281 @default.
• W2162295328 hasConcept C126322002 @default.

• next